$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
晚期肝癌的治疗靶向药物乐伐替尼先后获中美批准
2025-10-19 11:44:20
Check Details
肝癌患者服用乐伐替尼的治疗数据
2025-10-19 11:44:20
Check Details
服用乐伐替尼过程中需要注意那些小细节?
2025-10-19 11:44:20
Check Details
肝癌靶向药物乐伐替尼
2025-10-19 11:44:20
Check Details
乐伐替尼在肝癌、肾癌以及甲状腺癌的研究数据
2025-10-19 11:44:20
Check Details
乐伐替尼治疗肝癌疾病控制率高达78%!
2025-10-19 11:44:20
Check Details
肝癌患者服用乐伐替尼多久有效果?价格相比又是怎样的?
2025-10-19 11:44:20
Check Details
乐伐替尼单药使用好还是联合其他药物使用好?
2025-10-19 11:44:20
Check Details
乐伐替尼治疗晚期肝细胞癌的2期研究
2025-10-19 11:44:20
Check Details
卡博替尼已成为索拉非尼耐药后的首选靶向药
2025-10-19 11:44:20
Check Details
老年肝癌患者服用索拉非尼的成本效益如何?
2025-10-19 11:44:20
Check Details
数据证明:肝癌患者服用索拉非尼获得的总生存期延长了44%
2025-10-19 11:44:20
Check Details
1
2
...
2556
2557
2558
2559
2560
2561
2562
...
4156
4157
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Lenvatinib Safety Guide: Baseline Assessment & Adverse Reaction Management
2
Inluriyo (Imlunestrant): Oral SERD for ER+/HER2- Breast Cancer with ESR1 Mutations
3
Idelalisib: Oral PI3Kδ Inhibitor for Relapsed/Refractory Hematologic Malignancies
4
Lorlatinib (Lorviqua): Oral Targeted Therapy for ALK-Positive Advanced Non-Small Cell Lung Cancer
5
FDA Approves Ibrance for New Maintenance Indication in HR+/HER2+ Breast Cancer
6
FDA Approves Trodelvy for Two First-Line Indications, Redefining Advanced Triple-Negative Breast Cancer Care
7
Cabozantinib: A Pan-Targeted TKI in Modern Oncology Practice
8
Managing Amivantamab Infusion Reactions: A Clinical Guide for International Practice
9
Onset Timeline and Efficacy Assessment of Margetuximab plus Chemotherapy in HER2-Positive Metastatic Breast Cancer
10
Avutometinib Plus Defactinib: A Precision Therapy for KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer
11
Vemurafenib (Zelboraf) Complete Medication Guide
12
Durvalumab Safety Profile: Managing Immune-Related Adverse Events (irAEs) in Clinical Practice